Member Info for Tornadotony

Uddin 179

Look at this way if someone nicked RM from the company with a higher pay offer, how much would the company lose in having to recruit another CEO. Bear in mind it would take anywhere from 3-5 months to fill the post and they have to hit the ground running. The answer could well be a great deal if the p3 study had a knock on delay of several more months.
Finally will anybody complain if the outcome is a business success. Time to question pay rises is when nothing happens and the CEO is more interested in an affair with the secretary and other versions of insider dealing.

Long term investors like to consider what happens further down the track as to ignore a lot of noise that may be happening at the present time. So let us work through a journey with a lot of assumptions being declared. Lets assume that the roll out of vaccines in many countries works well and that the vaccine is giving quite reasonable efficacy and life gets back to a more of what it was in 2019. Lets take the assumption that Synairgen has completed its P3 trials very late in 2021 and they were also promising. As the winter of 2021 approaches a smaller number of Covid-19 cases in older people still occur and some of the Synairgen product is put to use and adds to its product evidence and track and trace and surveillance stays on top of what is going on as it remains numerically manageable to deal with.

As 2022 progresses more mutations in what was Covid-19 continue and eventually someone finds the change significant enough to be renamed Covid-22. Now the industry may go on to produce another vaccine to follow the antigenicity of the new mutations and continue with a high efficacy rate. However there is always the possibility of a surge anywhere globally of either a new Covid virus version or that the depletion of immunity status from the first vaccine has worn off and immunological memory in many people has not been retained by this time and they can be susceptible to either the original Covid-19 as well as any newer version ( assuming boosters to Covid-19 were not universally taken up). These risks suggests to me that a therapeutic tool kit that has a more generic response to whatever evolves down the track in a couple of years time has a market intrinsic value. Politicians will not want a pandemic response failure to arise in their country when readily available solutions could have been deployed to contain the problem and the economic down stream pain will be visible or certainly known. Using a therapy can in-fill gaps arising from breaks in vaccinations programmes. The surveillance market elements still have a value in all of this as well.

It may therefore be that Synairgen has a future market from the coronaviruses. It may not be enormous, but as I have said before a £50M profit a year is £2 share price. The company may have consolidated a market position in COPD patients and other risk groups and may have stand-by volumes for distribution for pneumonia and influenza patients taken ill in hospital. It is therefore useful to consider that Synairgen may have seasonal or mutational response use that can in-fill gaps if and where they arise in the vaccine market.

At 79, 72 and 60p. Resistance is now at 85p. Forgive the chart data, but I am now watching out on this aspect.

I topped up at 6.36 to average down my entry. Agree with the fools errand comment but its handy to have more shares at this price.

At this rate should soon be evens.

In the process of re-engineering the portfolio. I want to wish everyone here good luck. Managed to leave with a gain.

Was hugely positive. If it were not for Covid-19 this would be shovel ready far sooner. It would be completely irresponsible to build a mine in the middle of a pandemic. The progress that was made is positive. The direction of travel is very clear. Economic demand for the end product is most likely to be delayed 6 months in any case because of Covid-19. The risk of a bigger company buying out HZM if anything has become greater or a desire to buy their second mine not being built yet has increased.

Just to confirm that the current pattern ends around 11 December or 14 December.

The consolidation is within a pennant shape with a rising base from 59p and a top line slow descent from 76p. The range is getting squeezed so it will soon be 61p to 74p and converge and eventually it converges on 67p. This may take a few days to play out. This kind of move in the chart in forming a pennant leads to a big move in the SP. It can go higher or lower when it breaks out of the support and resistance range as they converge. So all we know from a chart pattern like this is that a news event say late next week could generate and exaggerated move in the stock price. The news event could also be external to the company, but has a material impact. At the moment, I can not be sure what might come along and move the share from the 60's.

The execution of the Mandate is a key milestone in the project financing process for the development of Araguaia. BNPP, ING, Mizuho, Natixis and Société Générale have extensive experience in providing project financing to greenfield mining projects and were chosen as Mandated Lead Arrangers due to their extensive Latin American project finance experience and the strength of their mining teams.

Closing of the Facility, targeted for end of the calendar year 2020, remains subject to completion of due diligence in form and substance satisfactory to the MLAs, final credit approvals and execution of definitive Facility documentation.

I presume it is a case of working through all the administrative procedures. I presume if it overran more than a month, the company would update us with an RNS providing a new timeline for completion.

I believe in the fundamentals. The use of the chart becomes interesting when the stock has endured an external news shock. It also becomes useful when a company news flow is likely to be slow as the timelines for delivery are many weeks away. A number of AIM shares follow chart patterns especially when they get into a phase of consolidation. Volatility will finally create a definitive bottom. Chartists then start buying the stock. They use RSI and stochastics to sell and but and it creates a peak and the shares then challenge the low as a double bottom or they set a higher low and create a bullish signal. Chartists continue behaving the same way for a new higher peak and rinse and repeat the cycle when they believe the fundamentals. If enough people trade in that way the chart mechanics become self fulfilling until a news event arrives.

Some people can not stand chart people giving data and others love it. Its marmite mumbo jumbo to some and mathematics, no emotion that gives profit more than loss for others based on risk odds. Its helpful if people say they want chart info or they don't. Chart users won't post info if folks do not want to know. When they do post where they have gone in and coming out its usually not to show off.

https://www.marketscreener.com/quote/stock/SYNAIRGEN-PLC-4004905/

We have a new support line at 60p that was at 85p a few days ago. I am keeping my powder dry and despite the history of the chart going back only to July as relevance to a major RNS event change, I will be using it to make my own future Synairgen buying decisions.

The company will need to have a lot of focus in 2021. It may be more beneficial to have a small dividend and we have more Capex expenditure on developing assets. This looks like a company gearing for another big growth phase. I do feel the company should be given a better PE rating and upgraded. The copper prices are soaring and 25% of what the company is producing is likely to be copper.

artdralor

None of the vaccines would include the more rare conditions like Cystic Fibrosis. So the answer is untested and if they tested one person with CF that might not be statistically valid.
We will learn a great deal when the first 800,000 doses get used on the over 80's patient group. This will at least give a clear indication of true efficacy percentage. The efficacy of Astra Zenneca vaccine is known to be reasonable in older people but again large volumes vaccinated will give a clear read.

Once you know that is useful in high percentage of cases taken, after six months we should know it lasts long enough to be worthwhile. A year plus of protection is what we hope for.

The final piece is adverse vaccination outcomes. Again they will get recorded and 1 in 150,000 vaccinated having life changing chances is accepted for any vaccine. The state has mandatory funds for that 1 in 150,000 event for the benefit of all society so the unfortunate are at least financially covered.

Therefore the decision to be taken is what are the health risks for any individual not being vaccinated as against being vaccinated within the next 6 months, and that partly is influenced by community infection rates and other health conditions a person has. So I would consult with the primary care provider in the first incidence. A charity body for CF will know of healthcare professionals to consult and why not speak to them as well. From memory Cystic Fibrosis is very supportive to their patient community.

Tony

Suffolk Jim I asked for that post to be removed. Instead of can it should have been potentially as it was not tested for. Thanks for correcting.

Suffolk Jim I was doing things in a hurry this morning so will double check exact wording and apologise if I got it wrong. My intention is not to mis-report info.

This is not about suiting an agenda. Its about the formal process of approval and sharing of data. The public would I am sure like to read the trial data, the protocol and so forth. Everyone knows vaccines are to rolled and eventually approved. There is no coordination with FDA and EU regulators. All of this would be expected in a month's time. Furthermore, Synairgen's product is a broad based anti-viral. The company value is massively under rated without a Covid-19 market at all.

I personally feel that if we had accelerated peer review on the vaccines and approval was arrived at in mid-January and scientists had sight of the trial data than a lot of confidence would be generated to take the vaccine. When it rushed through it feels like the Titanic being raced towards an iceberg. At best regulators may have received the data two weeks ago. Moderna thought the earliest it could be approved was 22 December where as UK said it will be approved 8 December.

Lyndon69

Other vaccines will follow. AstraZenneca have at least tested their vaccine in a stage 2 study in older patients and it worked fine. I am not some kind of anti-vax person. I am just not happy with this Pfizer one. I am concerned that MHRA is approving the Moderna vaccine without actually studying the trial data. If the Moderna vaccine had accelerated peer review and was approved in January , I would have more confidence in the MHRA than a rushed decision. Tony

https://2020news.de/en/dr-wodarg-and-dr-yeadon-request-a-stop-of-all-corona-vaccination-studies-and-call-for-co-signing-the-petition/

Thanks to contributors on Synairgen board for previous and this one.